CompletedPhase 3

Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

Sweden22 participantsStarted 2008-09

Plain-language summary

This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participation in the GHNOO-1658 trial * Subject has completed genetic testing of PTPN11 mutation

What they're measuring

Change in height SDS (Standard Deviation Score) (referenced to normal population)

Timeframe: From baseline until final height is reached

Trial details

NCT IDNCT01529944

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-10

View on ClinicalTrials.gov More Genetic Disorder trials